In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

Goldman Sachs analyst Chris Shibutani maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $136.00.

In this article, we are going to take a look at where BioNTech SE (NASDAQ:BNTX) stands against the other best vaccine stocks to buy now. On February 24, CNBC reported that President Trump declared ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of ...

BioNTech is expanding its oncology pipeline with FixVac, iNeST, and BNT327 for individualized cancer treatments. Read why I ...

Analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of BioNTech in a research report ...

BioNTech SE (NASDAQ:BNTX – Get Free Report) was down 6.4% during mid-day trading on Tuesday after Morgan Stanley lowered their price target on the stock from $145.00 to $139.00.Morgan Stanley ...

Investors in BioNTech SE (Symbol: BNTX) saw new options begin trading today, for the June 2026 expiration. One of the key data points that goes into the price an option buyer is willing to pay ...

BioNTech has passed on Autolus Therapeutics’ dual targeting CAR-T cell therapy. One year after securing a chance to ...

Q4 2024 Earnings Call Mar 10, 2025, 8:00 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants. P ...

Welcome to BioNTech's Fourth Quarter and Full-Year 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor Relations. Please go ahead. Thank you.